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MaOBJECTIVES This study investigated the impact of the Medtronic AdaptivCRT (aCRT) (Medtronic, Mounds View,
Minnesota) algorithm on 30-day readmissions after heart failure (HF) and all-cause index hospitalizations.
BACKGROUND The U.S. Hospital Readmission Reduction Program, which includes a focus on HF, reduces Medicare
inpatient payments when readmissions within 30 days of discharge exceed a moving threshold based on national
averages and hospital-speciﬁc risk adjustments. Internationally, readmissions within 30 days of any discharge may
attract reduced or no payment. Recently, cardiac resynchronization therapy (CRT) devices equipped with the aCRT
algorithm allowing automated ambulatory device programming were introduced. The Adaptive CRT trial demonstrated
the algorithm’s safety and comparable outcome against a rigorous echocardiography-based optimization protocol.
METHODS Weanalyzed data from theAdaptive CRT trial,which randomizedpatients undergoingCRTdeﬁbrillation on a2:1
basis to aCRT (n¼ 318) or to CRT with echocardiographic optimization (Echo, n¼ 160) and followed up these patients for a
meanof20.2months (range:0.2 to31.3months). Logistic regressionwithgeneralizedestimatingequationmethodologywas
used to compare the proportion of patients hospitalized for HF and for all causes who had a readmission within 30 days.
RESULTS For HF hospitalizations, the 30-day readmission rate was 19.1% (17 of 89) in the aCRT group and 35.7%
(15 of 42) in the Echo group (odds ratio: 0.41; 95% conﬁdence interval [CI]: 0.19 to 0.86; p ¼ 0.02). For all-cause
hospitalization, the 30-day readmission rate was 14.8% (35 of 237) in the aCRT group compared with 24.8% (39 of 157)
in the Echo group (odds ratio: 0.54; 95% CI: 0.31 to 0.94; p ¼ 0.03). The risk of readmission after HF or all-cause index
hospitalization with aCRT was also signiﬁcantly reduced beyond 30 days.
CONCLUSIONS Use of the aCRT algorithm is associated with a signiﬁcant reduction in the probability of a 30-day
readmission after both HF and all-cause hospitalizations. (Adaptive Cardiac Resynchronization Therapy Study [aCRT];
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ABBR EV I A T I ON S
AND ACRONYMS
aCRT = AdaptivCRT
AV = atrioventricular
CMS = Centers for Medicare
and Medicaid Services
CRT = cardiac
resynchronization therapy
Echo = echocardiographic
optimization
HF = heart failure
HRRP = Hospital Readmissions
Reduction Program
LV = left ventricle
NYHA = New York Heart
Association
RV = right ventricle
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566C ardiac resynchronization therapy(CRT) is an established therapy forpatients with heart failure (HF)
symptoms, left ventricular (LV) systolic
dysfunction, and a wide QRS (1,2). CRT has
been shown to improve functional capacity
and quality of life (1), reduce mortality and
hospitalization (3,4), reverse the cardiac
remodeling process (1), and be cost-effective
(5–7). However, not all patients respond to
CRT (8), resulting in a failure to realize
maximal potential reductions in the inci-
dence of HF and repeated hospitalizations.SEE PAGE 573In the United States, the introduction of
the Affordable Care Act added to the SocialSecurity Act, and the Hospital Readmissions Reduc-
tion Program (HRRP) was established (9). This pro-
gram reduces all Medicare inpatient payments when
readmissions within 30 days of discharge from an
“index admission” exceed a moving threshold based
on national averages and hospital-speciﬁc risk ad-
justments. Inpatient admissions for HF were one of
the ﬁrst hospitalization types identiﬁed in the rules
of this program as relevant “index admissions.”
Although the United States and other countries have
different modes of implementation (10), reducing
early readmissions to the hospital is becoming an
international policy priority aimed at reducing costs
and improving the quality of health care (11).
The Adaptive CRT clinical trial (12) demonstrated
that a novel algorithm for delivering CRT was at least
as effective as protocol-driven echocardiographic
optimization. The time to ﬁrst HF admission was
found to be similar for aCRT patients and patients
who underwent traditional echocardiographic opti-
mization; the initial report that was published did not
include the overall number of admissions per patient
(HF or otherwise). The AdaptivCRT (aCRT) algorithm
(Medtronic, Inc., Mounds View, Minnesota) auto-
matically adjusts atrioventricular (AV) and interven-
tricular delays on the basis of frequent evaluation of
the patient’s underlying conduction (13). Speciﬁcally,
the algorithm provides LV-only pacing synchronized
to right ventricular (RV) activation when intrinsic
AV conduction is normal or biventricular pacing when
AV conduction is prolonged.
Whellan et al. (14) studied patients with CRT de-
vices and an HF hospitalization. These investigators
reported that risk of readmission within 30 days of
the index hospitalization was increased when certain
device-derived diagnostic criteria, such as high atrialﬁbrillation burden with poor rate control, were pres-
ent 7 days after the index hospitalization. Of note,
Martin et al. (15) also have reported a reduction in
atrial ﬁbrillation with use of the aCRT algorithm.
Despite the high volume of research in the risk of HF
hospitalization in general, we are not aware of any
other studies that evaluated the risk of readmission
within 30 days among patients with a CRT deﬁbril-
lator. In the present study, we evaluated the impact
of the aCRT algorithm on 30-day hospital readmission
rate compared with conventional CRT optimized by
echocardiography. We examined readmissions after
either HF or all-cause index hospitalization.
METHODS
The design and primary results of the Adaptive CRT
trial have been previously published (12,13). Brieﬂy,
the Adaptive CRT trial was a prospective, multi-
center, randomized, double-blind clinical trial
comparing aCRT with therapy dynamically adjusted
by the algorithm to standard biventricular pacing
with AV and interventricular settings optimized
through use of a standardized, rigorous, echocar-
diographic protocol (Echo arm). The trial enrolled
patients who did not have permanent atrial tachyar-
rhythmias and had clinical indications for implanta-
tion of a de novo CRT deﬁbrillator system. The
clinical indication at the time of enrollment was New
York Heart Association (NYHA) functional class III or
IV HF symptoms, LV ejection fraction of <35%, and
QRS duration of $120 ms while receiving optimal
medical therapy. Primary objectives were met,
demonstrating the algorithm’s safety and effective-
ness of improving patient 6-month response rate at a
rate similar to that of the Echo arm.
OUTCOME MEASURES. Data regarding all hospitali-
zations were collected prospectively during the trial.
Readmission within 30 days was assessed by identi-
fying “index hospitalizations” that could fall under
the HRRP or other international rules and deter-
mining for each one whether any subsequent hospital
readmission occurred >1 day and #30 days after
discharge. These readmissions would have been
counted toward ﬁnancial penalties. In alignment with
the manner in which the Centers for Medicare and
Medicaid Services (CMS) is measuring hospitals in
the United States, our analysis speciﬁed an index
hospitalization as having at least 30 days of patient
follow-up after discharge, and no hospitalization
was counted as both an index hospitalization and a
readmission. Both all-cause and HF-related index
hospitalizations were assessed. Hospitalizations for
device implants were included only if investigators
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567considered them to be related to HF. For hospitali-
zations lasting at least 24 h, relatedness to HF was
evaluated by a blinded event adjudication committee,
with the remaining hospitalizations evaluated by
the study investigator.
STATISTICAL ANALYSIS. Index hospitalizations were
the unit of analysis. Because of the aims of our anal-
yses, patients could contribute multiple index hos-
pitalizations and readmissions. All patients included
in the initial reporting of the Adaptive CRT Trial (12)
were looked at for these analyses. However, some
patients did not contribute any events because they
were never hospitalized during follow-up. The pro-
portion of index hospitalizations that resulted in
a readmission within 30 days were compared be-
tween study arms using the generalized estimating
equations logistic regression model. This analysis
accounted for the fact that the same patient may be
hospitalized more than once and that hospitalizations
for the same patient may have exhibited correlation
in the likelihood of readmission. The within-patient
correlation was modeled with a compound symme-
try working correlation. The generalized estimating
equations logistic regression model was also used for
subgroup analysis by assessing the interaction be-
tween study arm and subgroup variable. In addition,
time to readmission that extended beyond 30 days of
follow-up was described with Kaplan-Meier curves,
with study exit or death as censoring events, to assess
sensitivity to the readmission window. Time from
discharge to readmission was compared between
arms using a recurrent event proportional hazards
regression with a robust sandwich estimator of
the covariance to estimate the hazard ratio and
95% conﬁdence interval (CI) while accounting for
within-patient correlation. A score test using this
proportional hazards model was performed to assess
statistical signiﬁcance. All analyses were performed
with SAS software (version 9.2, SAS Institute, Cary,
North Carolina).
RESULTS
The Adaptive CRT trial randomized 478 patients
(318 aCRT and 160 Echo) (Online Table 1). Patients
were followed up for an average of 20.2 months
(range: 0.2 to 31.3 months). During that period, a total
of 570 hospitalizations occurred (337 aCRT and 233
Echo); 488 (290 aCRT and 198 Echo) of those lasted at
least 24 h and were adjudicated.
Of all 488 hospitalizations, 84 (56 aCRT and
28 Echo) were not considered index hospitalizations
because fewer than 30 days of follow-up were avail-
able after the hospitalization. The remaining 486hospitalizations were either index hospitalizations
or readmissions. Patients who had one or more index
hospitalizations during follow-up were included in
this analysis of 30-day readmissions (Figure 1). The
proportion of patients with at least one index hospi-
talization did not differ between arms for all-cause
hospitalizations (45.0% aCRT vs. 50.6% Echo; chi-
square test p ¼ 0.24) or HF-related hospitalizations
(19.2% aCRT vs. 16.9% Echo; chi-square test p ¼ 0.54).
Study baseline characteristics for patients who had an
index hospitalization are presented in Table 1. Pa-
tients were on average 65  12 years of age and
72% male. They had advanced heart failure with
94% NYHA functional class III, LV ejection fraction
of 24.3  6.7%, and QRS interval of 153  22 ms.
A high percentage of these patients were taking
angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers (86%) and beta-blockers
(90%). Patients who were hospitalized were similar
in the 2 arms, with the exception of angiotensin-
converting enzyme inhibitor or angiotensin receptor
blocker use, which was higher in the Echo arm (93.8%
vs. 81.8% aCRT; p ¼ 0.01).
The rate of readmission within 30 days after an all-
cause index hospitalization was 14.8% in the aCRT
arm versus 24.8% in the Echo arm. For HF-related
index hospitalizations, the aCRT arm had a 30-day
readmission rate of 19.1% versus 35.7% in the Echo
arm (Table 2). The rate was signiﬁcantly lower in the
aCRT arm than in the Echo arm for both all-cause
hospitalization (odds ratio [OR]: 0.54; 95% CI: 0.31
to 0.94; p ¼ 0.03) and HF-related index hospitaliza-
tion (OR: 0.41; 95% CI: 0.19 to 0.86; p ¼ 0.02).
This reduction was robust to the amount of time
over which readmission was assessed. Kaplan-Meier
curves in Figure 2 show that the reduction is main-
tained over up to 1 year of follow-up, with borderline
statistical signiﬁcance for all-cause index hospitali-
zations (p ¼ 0.051) and statistical signiﬁcance for
HF-related index hospitalizations (p ¼ 0.02), without
any signal of the impact attenuating over the period
of follow-up.
Because previously published analyses from the
trial examining improvement in Packer Clinical
Composite Score and time to ﬁrst HF hospitalization
or death showed signiﬁcant differences only in pa-
tients with normal AV conduction (16), we examined
the reduction in 30-day readmissions within the
normal and prolonged AV subgroups. An interaction
test was used to compare the ORs between the normal
and prolonged AV subgroups, examining whether the
degree of risk reduction for a 30-day readmission
seen in the aCRT arm differs between these sub-
groups. The interaction tests (Table 3) demonstrated
FIGURE 1 Patients Analyzed
Flow diagram of patients analyzed. CRT ¼ cardiac resynchronization therapy; HF ¼heart failure.
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568that the ORs were not statistically different between
the normal and prolonged AV subgroups either
for HF-related (p ¼ 0.25) or for all-cause index hos-
pitalizations (p ¼ 0.15). Similar analyses were per-
formed to assess possible differences in persons with
and without renal dysfunction and in different
geographic regions (Online Tables 2 and 3). No sig-
niﬁcant differences in 30-day readmission rates were
observed in these subgroups.
DISCUSSION
The aCRT algorithm is intended to safely replace
other forms of CRT optimization while leveraging
normal physiological conduction, when present.
Martin et al. (12) demonstrated that the primary
endpoint was reached in the pivotal trial (12). The
principal ﬁnding of this analysis is a striking and
robust relative reduction in both all-cause 30-day
readmissions (46%) and HF 30-day readmissions
(59%). Other studies have shown the impact of CRTon readmissions over a 6-month period, but this
study is the ﬁrst to demonstrate a reduction in the
30-day readmission rate with CRT and to speciﬁcally
utilize a novel algorithm to optimize resynchroniza-
tion therapy. These analyses, which include longer
follow-up and are based on outcome measures
different from the ones used in previous publications
(12), were not expected to produce the same metrics.
These ﬁndings are timely because the United States
and many other countries have deﬁned 30-day
readmissions as an important metric related to
reimbursement, ﬁnancial incentives, and quality
outcomes.
Acute readmissions have attracted heightened
attention lately, not least because of the HRRP
wherein CMS reduces all hospital inpatient reim-
bursement when readmissions within 30 days of
discharge for predetermined hospitalizations exceed a
threshold based on national averages and hospital-
speciﬁc risk adjustments. Effective October 1,
2014, CMS expanded this list of predetermined
TABLE 1 Baseline Patient Characteristics
aCRT Echo p Value
Age, yrs 143 (64.3  12.7) 81 (66.1  10.4) 0.30
LV ejection fraction, % 143 (24.1  6.6) 81 (24.7  6.8) 0.54
LV end systolic volume, ml 135 (145.6  56.2) 72 (157.9  84.8) 0.21
QRS interval, ms 141 (152.7  21.2) 81 (154.4  22.8) 0.57
6-min hall walk distance, m 138 (256.5  136.3) 78 (254.9  132.7) 0.93
Minnesota Living With
Heart Failure Score
128 (54.4  22.9) 69 (49.4  23.5) 0.15
Left bundle branch block 143 (71.3) 81 (77.8) 0.29
Male 143 (72.7) 81 (70.4) 0.71
Ischemic cardiomyopathy 143 (49.0) 81 (56.8) 0.26
NYHA functional class III 143 (92.3) 81 (97.5) 0.11
Taking an ACE inhibitor/ARB 143 (81.8) 81 (93.8) 0.01
Taking a beta-blocker 143 (89.5) 81 (90.1) 0.89
Values are n (mean  SD) or n (%).
ACE ¼ angiotensin-converting enzyme; aCRT ¼ AdaptivCRT; ARB ¼ angiotensin II receptor blocker; Echo ¼
echocardiographic optimization; LV ¼ left ventricular; NYHA ¼ New York Heart Association.
TABLE 2 Hospital Readmissions Within 30 Days After Discharge
Index Event Type
30-Day Readmission Rate
OR (95% CI) p ValueaCRT Echo
Heart failure 19.1 (17/89) 35.7 (15/42) 0.41 (0.19–0.86) 0.02
All cause 14.8 (35/237) 24.8 (39/157) 0.54 (0.31–0.94) 0.03
Values are % (# with readmission/# index).
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
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569hospitalizations to include chronic obstructive pul-
monary disease and total hip/knee arthroplasties in
addition to the previous list of HF, acute myocardial
infarction, and pneumonia hospitalizations. The
maximum penalty was also increased from 2% to 3%.
Many persons have questioned the appropriateness
of the rate of readmission within 30 days as a quality
metric (17), whereas others have suggested that an
increased rate is associated with better outcomes (18).
Despite the ongoing discussion, economic incentives
are currently in place with the goal of reducing
readmissions. Internationally, similar incentives
exist. The English National Health Service is not
providing reimbursement for any readmission within
30 days of any discharge (10). England also
established a qualitymetric onHFmortality. However,
a measure speciﬁc to HF readmissions has not
been implemented (19). Germany will not pay for
any readmission within 30 days of a hospitalization in
the same “major diagnostic category” (20). With
“cardiology” being such a category, the incentive is
broad and perhaps harsh because it forces hospitals to
absorb the full cost of additional care that may be
needed.
CRT has been demonstrated to reduce morbidity
and mortality and has the ability to reduce LV vol-
umes and improve ejection fraction (1–4,21,22). The
aCRT algorithm may have the ability to further
enhance the beneﬁts of CRT through reduced RV
pacing and frequent ambulatory optimization
(12,15,16,23). The current trial showed that aCRT is at
least as effective as echocardiography-optimized
CRT, reduces the need for manual optimization, and
may lower all-cause and HF 30-day readmissions.
A large global trial has now been launched and aims
to determine if the aCRT algorithm can reduce the
combined endpoint of all-cause mortality and inter-
vention for HF decompensation compared with
standard CRT (24). The 30-day readmissions after
HF hospitalization is a secondary endpoint. Further
studies will determine if enhanced LV pacing and
reduced RV pacing will maximize the beneﬁt of
CRT and reduce the small, yet important, group of
nonresponders.
Although the present trial does not provide evi-
dence to determine why aCRT is associated with
a striking reduction in readmissions, we propose
several hypotheses. The lack of difference in index
hospitalization rates between the 2 groups, for both
all-cause and HF-related index hospitalizations,
points to the possibility that aCRT may have a time-
dependent, physiological effect. Martin et al. (15)
have shown that patients with aCRT have a reduced
atrial ﬁbrillation burden, particularly after 12 monthsof follow-up. In addition, persons with a decrease in
left atrial size had the largest reduction in atrial
ﬁbrillation (15). These data suggest that LV-only
pacing and frequent interval optimization over time
is associated with beneﬁcial remodeling and a
reduction in atrial ﬁbrillation. Both of these factors
likely contribute to the reduction in 30-day read-
missions. Generally, a reduced atrial ﬁbrillation
burden would result in a greater percentage of time
with resynchronization pacing therapy, which has
been shown to improve outcomes. Reduced RV pac-
ing should retard ventricular remodeling, annular
dilation, tricuspid regurgitation, and right atrial
enlargement and hence delay atrial ﬁbrillation. The
importance of maximizing the dose of beta-blockers
is dogma, and we expect reduced RV pacing to
facilitate up-titration of medical therapies. Finally,
the algorithm’s frequent interval optimization may
provide a beneﬁt during increased demand at exer-
cise or over the course of cardiac remodeling or
CRT-induced reverse remodeling.
Although it is agreed that reducing readmissions
is an important objective, deﬁning the best way to
reduce readmissions has been elusive. Ultimately,
one might speculate that a disease-modifying therapy
would reduce readmissions. A CMS population
FIGURE 2 Kaplan-Meier Curves of Hospital Readmissions
Time from heart failure hospitalization to all-cause readmission (A). Time from all-cause
hospitalization to all-cause readmission (B). aCRT ¼ AdaptivCRT; Echo ¼ echocardio-
graphic optimization; HF ¼ heart failure.
TABLE 3 Subgroup Analysis of Hospital Readmissions Within 30 Days After Discharge
Index Event
Type Subgroup
30-Day Readmission Rate
OR (95% CI)
Interaction
p ValueaCRT Echo
Heart failure 0.25
Normal AV 14.3 (4/28) 38.5 (10/26) 0.21 (0.05–0.86)
Prolonged AV 21.3 (13/61) 31.3 (5/16) 0.62 (0.24–1.62)
All cause 0.15
Normal AV 10.3 (10/97) 26.5 (22/83) 0.33 (0.14–0.79)
Prolonged AV 17.9 (25/140) 23.0 (17/74) 0.76 (0.36–1.62)
Values are % (# with readmission/# index).
AV ¼ atrioventricular; other abbreviations as in Tables 1 and 2.
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570database study examined 3 areas that might have an
impact on readmissions and showed that care tran-
sitions might have the greatest impact (25). In a study
group of elderly persons with heart failure decades
ago, Rich et al. (26) demonstrated that a multidisci-
plinary team approach to patients with HF would
improve outcomes. More recently, various technolo-
gies including pressure sensors, thoracic impedance
alerts, telephone monitoring, and others have failed
to signiﬁcantly reduce 30-day readmissions (27–29).
Abraham et al. (30) have shown that the combination
of pulmonary artery pressure monitoring applied to a
standardized, goal-directed medical therapy algo-
rithm will signiﬁcantly reduce HF readmissions at
60 days. By reducing RV pacing and adjusting pacing
intervals frequently, the aCRT algorithm may pro-
mote structural changes in cardiac anatomy, affecting
the natural history of HF, as does CRT and other
primary therapies that have an impact on cardiac
structure and promote reverse remodeling. This hy-
pothesis is supported by evidence showing a reduc-
tion in readmissions.
In summary, the seminal observation of lower
30-day readmissions with aCRT suggests a physio-
logical beneﬁt incremental to CRT related to reduced
RV pacing and frequent optimization. Preliminary
evidence supports this hypothesis, and the post-
market trial comparing aCRT with standard CRT will
provide deﬁnitive evidence. Today aCRT can provide
a safe and effective therapy that will also reduce
readmissions and hence overall health care costs.
Importantly, with aCRT being automated, it can be
expected to have an impact largely independent of
human factors.
STUDY LIMITATIONS. The sample size and the
numbers of events (readmissions) were relatively
small. This trial was a global trial, and signiﬁcant
differences in readmission rates and length of stay
based on region and country have been demonstrated
in an acute HF trial (31). Indications for readmission
were not standardized and were at the discretion of
the site investigator; in a way, this situation may
actually represent a better portrayal of real-world
effects because investigators could act as they
wished. CMS readmission rules were not enacted
during the study period. The effect observed may
be limited to CRT NYHA functional class III/IV indi-
cated patients because NYHA functional class II and
recently expanded AV block indicated patients were
not included in the trial. Lastly, CMS readmission
rules have been slightly modiﬁed from year to year,
and it is possible that unpredictable future modiﬁ-
cations to the rules may have a material impact on
these results.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Compared with
conventional CRT optimized by echocardiography, aCRT was
associated with a signiﬁcant reduction in 30-day readmissions
after both HF and all-cause hospitalizations. In select pa-
tients with advanced HF and wide QRS, aCRT may be a
favorable treatment option compared with conventional
CRT because of the observed reduced risk of hospital
readmission.
TRANSLATIONAL OUTLOOK: More studies are needed to
assess whether the observed reduced readmissions with aCRT
provides a meaningful impact to sustain improved patient
outcomes.
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571CONCLUSIONS
CRT, a proven therapy for patients with systolic HF,
improves survival and reduces HF-related morbidity.
The aCRT algorithm has been shown to improve the
therapy response rate in select patients, and this novel
delivery of therapy is associated with reduced 30-day
readmissions in patients with advanced HF. The obser-
vation of reduced readmissions with aCRT suggests a
physiological beneﬁt related to reduced RV pacing and
frequent optimization. Whether the aCRT algorithm
provides a meaningful impact to sustain improved
patient outcomes warrants further investigation.
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